Renovaro Biosciences ( (RENB) ) has provided an announcement.
The Company has entered into a new consulting agreement with Tarsh PB Advisors, effective November 4, 2024, for Simon Tarsh’s role as Interim CFO. Under the agreement, Tarsh PB Advisors will receive $25,000 per month, with potential bonuses and stock options contingent on specific milestones. The contract is initially for three months, with options for monthly renewals, and can be terminated with thirty days’ notice.
See more data about RENB stock on TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Adds an Ad-Supported Tier in Europe
- How Ford (NYSE:F) Looks to Solve Its Hydrogen Engine Problem
- The Intel (NASDAQ:INTC) “Coffee Debacle” Is Now Solved
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
